An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Inclusion Criteria

• Histologically confirmed Stage 4 or recurrent non-small cell lung cancer
• Eastern Cooperative Oncology Group (ECOG) score 0-1 (Physically able to carry out light housework or office work through to being fully active as you were before cancer)
• No prior systemic anticancer therapy (including EGFR and ALK inhibitors)
• Tissue or Programmed death-ligand 1 (PD-L1) results available Cohort 1A Inclusion Criteria:
• Eastern Cooperative Oncology Group (ECOG) score 2 or
• Eastern Cooperative Oncology Group (ECOG) score 0-1 and one disease specific criteria as listed in the protocol Cohort C Inclusion Criteria:
• High Tumor Mutation Burden

Exclusion Criteria

• Untreated brain metastases
• An active malignancy that requires concurrent intervention
• Active, known or suspected autoimmune disease
• Carcinomatous meningitis, which means there is inflammation of the covering of the brain, caused by cancer Other protocol-defined inclusion/exclusion criteria apply